The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands
Journal Title: Otolaryngologia Polska - Year 2013, Vol 67, Issue 5
Abstract
Introduction: The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor. Aim: The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies. Materials and methods: Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed. Results: The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor – salivary duct carcinoma. Conclusion: HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
Authors and Affiliations
Wojciech Golusiński, Anna Wegner, Paweł Trzeciak, Marcin Sówka, Andrzej Kopczyński, Małgorzata Bromboszcz
Keywords
Related Articles
- EP ID EP52212
- DOI -
- Views 101
- Downloads 0
Primary head and neck malignant melanomas in the data of ENT Department of Silesian Medical University: histo-clinical analysis
SUMMARY Introduction: In 2008 in Poland, there were over 2,200 cases of malignant melanomas. This tumor is characterized by considerable malice. Malignant melanoma of the head and neck region is a vast concept. Therefore...
Odległe wyniki estetyczne chirurgicznego leczenia wrodzonych zniekształceń nosa porównanie oceny pacjenta i chirurga
Carcinoma of the Iarynx in Region of Warmia and Mazury (1998-2007): epidemiological and clinical analysis and assessment of treatment results
Analiza średniego ciśnienia tętniczego krwi i częstości akcji serca u chorych operowanych z powodów laryngologicznych w okresie przedoperacyjnym oraz śródoperacyjnym i pooperacyjnym
SUMMARY Introduction: This work aimed to analyse the mean arterial blood pressure (MBP) and heart rate (HR) in patients who underwent Iaryngological surgery within the preoperative, perioperative and postoperative period...
Assessment of the efficiency of the auditory training in children with dyslalia and auditory processing disorders
SUMMARY Aim: To assess effectiveness of the auditory training in children with dyslalia and central auditory processing disorders. Materia! and Method: Materia) consisted of 50 children aged 7-9-years-old. Children with...